Demonstration of immunogenicity with the poorly immunogenic B16 melanoma - PubMed (original) (raw)
. 1983 Aug;43(8):3507-10.
- PMID: 6861123
Demonstration of immunogenicity with the poorly immunogenic B16 melanoma
C Celik et al. Cancer Res. 1983 Aug.
Abstract
Animal tumors of spontaneous origin have consistently been found to be less immunogenic than are tumors induced by chemical carcinogens or oncogenic viruses. Spontaneous tumors rarely demonstrate significant immunogenicity in classical transplantation rejection tests. This study demonstrates a novel approach to the question of tumor immunogenicity using viable tumor cells in diffusion chambers. Classical transplantation rejection was induced to the poorly immunogenic, spontaneous B16 murine melanoma by implantation of diffusion chambers containing viable B16 melanoma tumor cells. Implantation of B16 chambers i.p. for at least 4 weeks induced specific, long-term resistance to subsequent live B16 tumor cell challenge. In contrast, immunization with irradiated tumor cells for the same time interval resulted in a delay of tumor growth but had no effect on survival. These studies demonstrate the possibility that a significant anti-tumor immune response against the B16 melanoma may be induced without the presence and negative regulatory influences of a progressively growing B16 tumor. In addition, the diffusion chamber sensitization technique may detect the antigenicity of some tumors which are not detectable by classical transplantation rejection tests. Thus, the diffusion chamber technique provides another avenue for testing the immunogenicity of tumors, especially those of spontaneous origin.
Similar articles
- Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC, Abrams JT, Zhang SY, Galili U. LaTemple DC, et al. Cancer Res. 1999 Jul 15;59(14):3417-23. Cancer Res. 1999. PMID: 10416604 - Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG. Melcher A, et al. Cancer Res. 1999 Jun 15;59(12):2802-5. Cancer Res. 1999. PMID: 10383135 - Cancer and the immune system.
Karakousis CP. Karakousis CP. J Med. 1980;11(5-6):449-58. J Med. 1980. PMID: 6187876 Review. - Defining Immunogenic and Radioimmunogenic Tumors.
Medler TR, Blair TC, Crittenden MR, Gough MJ. Medler TR, et al. Front Oncol. 2021 Mar 19;11:667075. doi: 10.3389/fonc.2021.667075. eCollection 2021. Front Oncol. 2021. PMID: 33816320 Free PMC article. Review.
Cited by
- Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies.
Wu MH, Valenca-Pereira F, Cendali F, Giddings EL, Pham-Danis C, Yarnell MC, Novak AJ, Brunetti TM, Thompson SB, Henao-Mejia J, Flavell RA, D'Alessandro A, Kohler ME, Rincon M. Wu MH, et al. Nat Commun. 2024 May 24;15(1):4444. doi: 10.1038/s41467-024-48653-y. Nat Commun. 2024. PMID: 38789421 Free PMC article. - New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A, Bastiancich C, Bausart M, Ligot S, Lambricht L, Vanvarenberg K, Ucakar B, Gallez B, Préat V, Vandermeulen G. Lopes A, et al. J Immunother Cancer. 2021 Apr;9(4):e001243. doi: 10.1136/jitc-2020-001243. J Immunother Cancer. 2021. PMID: 33795383 Free PMC article. - Yap suppresses T-cell function and infiltration in the tumor microenvironment.
Stampouloglou E, Cheng N, Federico A, Slaby E, Monti S, Szeto GL, Varelas X. Stampouloglou E, et al. PLoS Biol. 2020 Jan 13;18(1):e3000591. doi: 10.1371/journal.pbio.3000591. eCollection 2020 Jan. PLoS Biol. 2020. PMID: 31929526 Free PMC article. - Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
Song W, Shen L, Wang Y, Liu Q, Goodwin TJ, Li J, Dorosheva O, Liu T, Liu R, Huang L. Song W, et al. Nat Commun. 2018 Jun 8;9(1):2237. doi: 10.1038/s41467-018-04605-x. Nat Commun. 2018. PMID: 29884866 Free PMC article. - Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.
Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Waickman AT, et al. Cancer Immunol Immunother. 2012 Jun;61(6):917-26. doi: 10.1007/s00262-011-1155-7. Epub 2011 Nov 25. Cancer Immunol Immunother. 2012. PMID: 22116345 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical